Loading patent…
AssigneeMax-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
InventorsDirk GÖRLICH, Metin AKSU, Oleh RYMARENKO, Thomas GÜTTLER, Renate REES, Kathrin GREGOR, Waltraud TAXER, Jürgen SCHÜNEMANN, Matthias DOBBELSTEIN, Kim Maren STEGMANN, Antje DICKMANNS
Estimating the term…
The present invention pertains in the fields of antibody technology, protein engineering, medicine, pharmacology, infection biology, virology, and medical diagnostics. More specifically, the present disclosure provides VHH antibodies that prevent cell entry of and infection by SARS-CoV-2 and that have been selected for potent cross-reaction and cross-neutralization between the original Wuhan strain and the Alpha, Beta, Gamma, Delta, and Mu variants of concern.
1-15. (canceled)
A VHH antibody recognizing the SARS-COV-2 spike protein S1 domain, particularly the receptor-binding domain (RBD) of the SARS-COV-2 S1 domain comprising
Dependencies are inferred from the claim text.